BioSpace News Archive

ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced a change in the location of its 2020 Annual Meeting of Stockholders. In light of the COVID-19 pandemic and in an effort to protect the health and safety of the Company’s stockhold

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 2

The Rockefeller Foundation announced that five new members have joined its Testing Solutions Group, a demand-driven coalition committed to scaling up access to testing for COVID-19.

RESTEM, a leading cell-based therapeutics company, announced today it has received approval from the U.S. Food and Drug Administration (FDA) for a 60-patient Phase I/IIa study using umbilical cord mesenchy

Additional Horizon data accepted as a poster presentation at ENDO 2020 summarize the first U.S.-based assessment of the GO-QOL questionnaire and demonstrate the significant burden of Thyroid Eye Disease on patient quality of life -- DUBLIN--( BUSINESS WIRE )-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that provide important insights into the mechanisms of TEPEZZA™ (teprotumumab-trbw), illustrating its pharmacokinetic (PK) pr

Data from more than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented during the upcoming American Society of Clinical Oncology ASCO20 Virtual Scientific Program and the European Hematology Association EHA25 Virtual Congress.

Senseonics Holdings, Inc. announced that three Medicare Administrative Contractors, Palmetto, First Coast Service Options and Novitas have removed implantable continuous glucose monitors such as Eversense from their non-coverage policy.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the Virtual Edition of the European Hematology Association (EHA) Annual Congress to be held online from June 11-14, 2020. The abstracts are availabl

Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25 th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually. The presentation, entitled Narsoplimab (OMS721) for the Treatm

PPD, Inc. has been recognized for excellence in clinical research for the ninth consecutive year by pharmaceutical and biotech professionals surveyed for Life Science Leader magazine’s 2020 CRO Leadership Awards.